Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Blimey what's kicked off here today? Anyone would think we'd dropped 50%.
Those asking questions - you know who can answer them - the company. So how qbout emailing them and getting your answers instead of clogging the board with rubbish.
It's a nice peaceful board normally
Not long to wait now for more news
Have a good weekend to the normal lths
@RB
I haven't said anything here what so ever that is in anyway negative.
That is dam unfair, I hold stock here and i remain a MASSIVE fan of the exceptional work that Suzy is doing
So leave it out...
And 4D has FA to do with VAL, they are both suffering as a result of the decline in the Bio index. I like a diverse portfolio that's why i also hold mining stocks and PMs.
@Teamhanz
Fair point- just wondering if there was an alternative way to address this that is all. I would certainly give my backing if its needed.
GLA
100 % Rightback. DDDD will need some huge funding around now so Porky can buy more over at DDDD if a placing happens with them. The same questions all the time.
I have had next week penciled in for a long time due to the end of year financials due during the Queen Jubilee week. Could be the last rush before the big news.
Bob back over to DDDD Porky mate you've trashed there SP with all your b******* theories and your back trying it on us.
Morning all.
The Clarets live to fight another day... Sunday should be fun v the Geordies then Val's rns Monday morning happy days to come.
Trials are independent Porky. You can’t conduct your own phase 3 hahaha.
Porky9
Social media has becomed the drug of choice for billions of people . No wonder the world has lost it's sense of priority. Lips fillers ,and botox injections now take precedence over cancer treatment.
@Andysel
It's so annoying as really in the bigger picture its not actually that much cash to fully fund a P3. Just more than they have currently hence the need for a partner to help fund this stage. 20m USD that's about 16m Sterling.
You can see from Suzy's video the potential of 201:-
https://www.brrmedia.co.uk/broadcasts-embed/6054a285d2ba3d1fb050c62e/valirx-val201-presentation/?popup=true
So here we have a potential UK developed drug with #lifechanging potential and it comes down to just a few quid to move it closer to market.
Meanwhile; don't get me started on the likes of Musk chucking 40 odd billion at a social media platform yet here a fraction of that would make such a difference...
Anyhow see how events unfold, still 6 weeks to go to end of long stop so plenty of time for RX to complete.
GLA
'Let's wave a magic wand and assume they acquire or kit out own lab
Does anyone know if they have the skill sets to continue working on 201 without TRX to go it alone and position it themselves for the next phase of trials?
Apart from cash do the Americans bring much else to the party? Anyone know?'
I was asking about the Americans (THx) in my debut post but was told suzy had informed all that thx had gone stealth as that supposedly benefits negotiations? Not much if any info on the Americans online..when thx formed? Or showreel for the two main guys showcasing experience of doing similar fundraising in past etc..Suzy and team of course must have done all checks on them obviously.
Talk on here about Suzy doing more but was thinking what more can she do in regards of the deal. Surely it all lies with thx and those looking to invest...thx have to sell it as a good opportunity And maybe world events and related economic issues are effecting minds potential investors
@Porky
Average costs for clinical trials
Phase 1 - $4m
Phase 2 - $13m
Phase 3 - $20m
The chart on the link gives slightly more detail based on area https://www.sofpromed.com/how-much-does-a-clinical-trial-cost
Hoosierdaddy- curious where u got 7 wks past the long stop date? Last rns stated 'As announced on 2 November 2021, ValiRx entered into a non-binding Letter of Intent ("LOI") with TheoremRx for the sub-license of VAL201. The LOI has been re-executed with an exclusivity period expiring before the end of June 2022.'
From this (maybe naively) I have in my own mind that the long stop date is end of June? Or have I missed something?
There's still approximately another 6 wks till the last day of June. . . . .
Imo there is still time :o)
@Porky
In answer to your question I don’t know how much it would cost, but to take 201 to trial ourselves would mean changing the company strategy again, which I don’t think will happen. Just my opinion,
@Andysel
The lab is a massive value add to the long term plans, makes sense and will get covered imo.
I am very confident of that. No wand required.
Let me rephrase my second question; on the assumption then that you think they have the skills to develop 201 in the trials themselves. How much cash approximate would it take to fund inhouse the trial stages? Could shareholders support that cost to get it over the line?? What are we talking??
As far as I'm concerned 201 is potentially an amazing asset , when that drug is positioned the Value will be significant. I'm thinking can it all be done in the UK without creating a stateside SPV and US involvement?
Interested if anyone has ideas on this, if not i will try and research how other Bios have done it and the costs involved....
should have read "the lab would be to enable"
@ Porky
Let's wave a magic wand and assume they acquire or kit out own lab - we don't have a magic wand
Does anyone know if they have the skill sets to continue working on 201 without TRX to go it alone and position it themselves for the next phase of trials? - VAL do have the skill set as they have/are being instrumental in assessing the vendors for the trials, the issue is funding the clinical trials.
The Lab would not be to enable VAL to carry out their assessments on future opportunities in house rather than outsourcing as they currently do, and in addition charge others for their services creating a revenue stream.
Apart from cash do the Americans bring much else to the party? Anyone know? - for this we will have to wait and see what else they bring to the table when the sub license has been completed.
Let's wave a magic wand and assume they acquire or kit out own lab
Does anyone know if they have the skill sets to continue working on 201 without TRX to go it alone and position it themselves for the next phase of trials?
Apart from cash do the Americans bring much else to the party? Anyone know?
You had me at Hello Batman!
If you weren’t such a total ball bay riggy I would like you as you really are rather amusing. Last person I really liked got blown up in a old factory by a lunatic with a large smile.
And here we are, the 19th of May 7 WEEKS past her absolute long stop date and not a sausage. But, at least they are constantly updating us how much they appreciate all these other companies doing their own work.... Here's an idea for you Suzy, Instead of appreciating all their hard work, no doubt benefitting their own share holders, get on the phone to TRX, The mysterious Japanese company, and let your shareholders be the one's tweeting how appreciative we are of our CEO for getting 201 deal done. Sayonara
For what it’s worth here is my take on it
TRX have been very smart. They have let the timelines slip because it helps there negotiating position
The longer this goes right, the more the market wobbles and shareholders get jittery. Also the cash burn continues and any cash raise gets closer if no deal is done. Then the dilution becomes more likely and the spiral continues.
TRX then offer to save the day on a cut price commercial deal, because they hold the cards on the exclusivity.
I’ve said this from the start Val are commercially naive, not being harsh, this is my own view
Others may think differently but I will only change my view once I see real evidence of something to the contrary
I’m buyer and a long term holder before everyone starts to jump down my throat!
Sonnets said "Personally, if the current extension is missed; I think Val should move on."
To what exactly? Dr Dilly is going to look like another "all mouth and no trousers" CEO if this US deal fails and is followed by a fund raise.
The company will likely need funding if 201 deal fails with TRX,don’t forget we aren’t a 1 trick pony,201 as much as it’s important for investor confidence is well down the list of company transforming products that Valirx are dealing with.
The problem is they might have to do a placing to move on as the company appears to need funding very soon and investors would be upset if convertible loans were used again.
If Val is top of the List why dont TheoremRx raise specifically for it and deal with the balance financing separately if indeed it is the balance or part(s) within that are the reasons for the delays thus far.
Personally, if the current extension is missed; I think Val should move on.
It comes down to believe in your ceo or don’t,both companies seem tight as a drum so no leaks coming.
Hold tight and add for me.
I'm starting to suspect Dr Ken used to go by the surname McKenzie....
https://youtu.be/PGDKTTNXH2w